PL2945642T3 - Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom - Google Patents
Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobomInfo
- Publication number
- PL2945642T3 PL2945642T3 PL14700872.6T PL14700872T PL2945642T3 PL 2945642 T3 PL2945642 T3 PL 2945642T3 PL 14700872 T PL14700872 T PL 14700872T PL 2945642 T3 PL2945642 T3 PL 2945642T3
- Authority
- PL
- Poland
- Prior art keywords
- protein
- treating
- factor
- preventing diseases
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13151593 | 2013-01-17 | ||
| PCT/EP2014/050788 WO2014111458A2 (en) | 2013-01-17 | 2014-01-16 | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2945642T3 true PL2945642T3 (pl) | 2024-07-29 |
Family
ID=47559322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14700872.6T PL2945642T3 (pl) | 2013-01-17 | 2014-01-16 | Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10369198B2 (enExample) |
| EP (2) | EP3747457A3 (enExample) |
| JP (4) | JP6809789B2 (enExample) |
| CN (6) | CN110903378A (enExample) |
| CA (1) | CA2898128A1 (enExample) |
| DK (1) | DK2945642T3 (enExample) |
| ES (1) | ES2986021T3 (enExample) |
| FI (1) | FI2945642T3 (enExample) |
| HR (1) | HRP20240623T1 (enExample) |
| HU (1) | HUE068364T2 (enExample) |
| LT (1) | LT2945642T (enExample) |
| PL (1) | PL2945642T3 (enExample) |
| PT (1) | PT2945642T (enExample) |
| RS (1) | RS65553B1 (enExample) |
| SI (1) | SI2945642T1 (enExample) |
| WO (1) | WO2014111458A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014111458A2 (en) * | 2013-01-17 | 2014-07-24 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| CA2956256A1 (en) * | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| US10435757B1 (en) | 2016-06-15 | 2019-10-08 | University Of South Florida | Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof |
| CN108802372B (zh) * | 2018-06-19 | 2021-05-11 | 上海伦泽生物科技有限公司 | 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒 |
| CN115698048A (zh) | 2020-01-21 | 2023-02-03 | 勃林格殷格翰国际有限公司 | 用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 |
| CN114149500B (zh) * | 2020-09-07 | 2023-12-01 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用 |
| CN114149498B (zh) * | 2020-09-07 | 2023-12-05 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体在防治2型糖尿病中的应用 |
| CN114149499B (zh) * | 2020-09-07 | 2023-12-05 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用 |
| EP4267594A1 (en) | 2020-12-23 | 2023-11-01 | Boehringer Ingelheim International GmbH | Viral capsid proteins with specificity to heart tissue cells |
| AU2022307365A1 (en) * | 2021-07-08 | 2024-02-01 | Tenaya Therapeutics, Inc. | Optimized expression cassettes for gene therapy |
| KR20250031229A (ko) | 2022-06-03 | 2025-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 골수 유래된 성장 인자의 재조합 발현 |
| WO2024052563A1 (en) | 2022-09-08 | 2024-03-14 | Boehringer Ingelheim International Gmbh | Myeloid-derived growth factor for use in treating cardiogenic shock |
| TW202528339A (zh) | 2023-09-01 | 2025-07-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療或預防肝臟病症之骨髓源性生長因子 |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| US20250186549A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
| CN120738287A (zh) * | 2025-07-03 | 2025-10-03 | 广州医科大学附属妇女儿童医疗中心 | 急性低灌注动物模型的构建方法及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| JP2002500502A (ja) | 1996-06-11 | 2002-01-08 | メルク エンド カンパニー インコーポレーテッド | 合成ｃ型肝炎遺伝子 |
| JP2001506484A (ja) * | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| CA2265923A1 (en) * | 1996-09-13 | 1998-03-19 | Sagami Chemical Research Center | Human proteins having secretory signal sequences and dnas encoding these proteins |
| WO2002008284A2 (en) * | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2000073445A2 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) |
| PL334902A1 (en) * | 1997-01-29 | 2000-03-27 | Cornell Res Foundation Inc | Repeatable local delivery of adenoviral vector in order to induce angiogenesis |
| DE60045243D1 (de) | 1999-05-26 | 2010-12-30 | Next Biomed Technologies Nbt Oy | VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN |
| WO2001012669A1 (en) * | 1999-08-16 | 2001-02-22 | Universita' Degli Studi Di Siena | Vegf-d and angiogenic use thereof |
| WO2002081681A1 (fr) * | 2001-03-30 | 2002-10-17 | Chugai Seiyaku Kabushiki Kaisha | Nouvelle utilisation de la cytokine sf20 |
| DE10119804A1 (de) * | 2001-04-23 | 2002-10-24 | Brahms Ag | Entzündungsspezifische Peptide und deren Verwendungen |
| WO2004060867A2 (en) | 2003-01-02 | 2004-07-22 | Timothy Kirk Gallaher | Secreted protein factor and cell membrane-bound splice variant |
| WO2004069173A2 (en) * | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US8486438B2 (en) | 2004-01-29 | 2013-07-16 | Brown University | Methods for progenitor cell recruitment and isolation |
| CN101160055A (zh) * | 2005-02-16 | 2008-04-09 | 莱蒂恩公司 | 慢病毒载体及其用途 |
| US20080004232A1 (en) * | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| EP2130547A1 (en) * | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| PE20121647A1 (es) * | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| US8735342B2 (en) | 2010-01-27 | 2014-05-27 | Neumedicines, Inc. | Method for treating brain cancer using a novel tumor suppressor gene and secreted factor |
| KR20120095063A (ko) * | 2011-02-18 | 2012-08-28 | 가톨릭대학교 산학협력단 | ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
| WO2014111458A2 (en) * | 2013-01-17 | 2014-07-24 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
-
2014
- 2014-01-16 WO PCT/EP2014/050788 patent/WO2014111458A2/en not_active Ceased
- 2014-01-16 LT LTEPPCT/EP2014/050788T patent/LT2945642T/lt unknown
- 2014-01-16 SI SI201432073T patent/SI2945642T1/sl unknown
- 2014-01-16 PT PT147008726T patent/PT2945642T/pt unknown
- 2014-01-16 CN CN201911137855.8A patent/CN110903378A/zh active Pending
- 2014-01-16 US US14/759,852 patent/US10369198B2/en active Active
- 2014-01-16 ES ES14700872T patent/ES2986021T3/es active Active
- 2014-01-16 CA CA2898128A patent/CA2898128A1/en active Pending
- 2014-01-16 CN CN201911124174.8A patent/CN110894226A/zh active Pending
- 2014-01-16 DK DK14700872.6T patent/DK2945642T3/da active
- 2014-01-16 CN CN201911137854.3A patent/CN110922468B/zh active Active
- 2014-01-16 CN CN201911137853.9A patent/CN111100197B/zh active Active
- 2014-01-16 JP JP2015553072A patent/JP6809789B2/ja active Active
- 2014-01-16 EP EP20178045.9A patent/EP3747457A3/en active Pending
- 2014-01-16 FI FIEP14700872.6T patent/FI2945642T3/fi active
- 2014-01-16 HR HRP20240623TT patent/HRP20240623T1/hr unknown
- 2014-01-16 CN CN201480005079.5A patent/CN104968361B/zh active Active
- 2014-01-16 HU HUE14700872A patent/HUE068364T2/hu unknown
- 2014-01-16 CN CN201911138039.9A patent/CN110922467A/zh active Pending
- 2014-01-16 PL PL14700872.6T patent/PL2945642T3/pl unknown
- 2014-01-16 EP EP14700872.6A patent/EP2945642B1/en active Active
- 2014-01-16 RS RS20240548A patent/RS65553B1/sr unknown
-
2020
- 2020-08-11 JP JP2020135954A patent/JP7685737B2/ja active Active
-
2022
- 2022-11-08 JP JP2022178566A patent/JP2023025005A/ja active Pending
-
2025
- 2025-06-03 JP JP2025092726A patent/JP2025143268A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2945642T3 (pl) | Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom | |
| SG11202012656WA (en) | Heterocyclic compounds useful in the treatment of disease | |
| IL242610A0 (en) | History of pyrazolopyrrolidine and their use in the treatment of diseases | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| ZA201601430B (en) | Insecticidal proteins and methods for their use | |
| ZA201509369B (en) | Insecticidal proteins and methods for their use | |
| PL3010506T3 (pl) | Pridopidyna w leczeniu choroby huntingtona | |
| SG10201709090UA (en) | Sobetirome in the treatment of myelination diseases | |
| EP2991600A4 (en) | MICRO-CLOSURES AND ASSOCIATED METHODS FOR TREATING SKIN | |
| HRP20181169T1 (hr) | Predlijekovi fumarata i njihova upotreba u liječenju različitih bolesti | |
| IL242770B (en) | A therapeutic combination that includes oxazolidinone-quinolones for use in the treatment of bacterial infections | |
| PL3466425T3 (pl) | Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych | |
| PL3004112T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| PL3044229T3 (pl) | Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej | |
| PL3041831T3 (pl) | Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby | |
| PL2943215T3 (pl) | Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| GB2510477B (en) | Formulations for use in the treatment of chronic fatigue and associated conditions, etc | |
| EP3085710A4 (en) | Protein and use thereof in treating multiple sclerosis | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| ZA201302565B (en) | Methods for treating hyperuricemia and related diseases | |
| GB201314623D0 (en) | Novel mucinase for use in therapy or prophylaxis |